title: Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate.
abstract: Bone scan index (BSI) is an objective tool for quantifying bone metastasis load. We assessed its prognostic usefulness in patients with metastatic castration-resistant prostate cancer (CRPC) treated with enzalutamide (ENZ) or abiraterone acetate (AA).
  
  
  
  We analyzed 40 patients who received ENZ or AA treatment (ENZ/AA) for metastatic CRPC. The Cox proportional hazards model and a C-index were used to investigate associations between overall survival (OS) and BSI, and patient age, prostate-specific antigen, time to CRPC, previous docetaxel use, and pain.
  
  
  
  Median OS after ENZ/AA was 17.8 months. All patient deaths (n = 19; 47.5%) were from prostate cancer. In multivariate analysis, decreased BSI was an independent predictor for longer OS (hazard ratio, 8.97; P = .011). Inclusion of BSI improved the C-index from 0.721 to 0.792 in predicting OS after ENZ/AA.
  
  
  
  Decreased BSI after ENZ/AA independently predicts longer OS.
authors.affiliation: Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan. Electronic address: miyoyasu@med.yokohama-cu.ac.jp.
authors.forename: Yasuhide
authors.initials: Y
authors.lastname: Miyoshi
authors.affiliation: Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Koichi
authors.initials: K
authors.lastname: Uemura
authors.affiliation: Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Kawahara
authors.affiliation: Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Shuko
authors.initials: S
authors.lastname: Yoneyama
authors.affiliation: Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Hattori
authors.affiliation: Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Jun-Ichi
authors.initials: JI
authors.lastname: Teranishi
authors.affiliation: Department of Urology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.
authors.forename: Jun-Ichi
authors.initials: JI
authors.lastname: Ohta
authors.affiliation: Department of Radiology, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Shigeo
authors.initials: S
authors.lastname: Takebayashi
authors.affiliation: Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: Yumiko
authors.initials: Y
authors.lastname: Yokomizo
authors.affiliation: Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: Narihiko
authors.initials: N
authors.lastname: Hayashi
authors.affiliation: Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Yao
authors.affiliation: Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Hiroji
authors.initials: H
authors.lastname: Uemura
mesh_terms: D000069501:Abiraterone Acetate / Q000008:administration & dosage* / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001549:Benzamides; D018450:Disease Progression; D006801:Humans; D007610:Kallikreins / Q000097:blood; D008297:Male; D008875:Middle Aged; D009570:Nitriles; D010669:Phenylthiohydantoin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood / Q000188:drug therapy*; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D009570:Nitriles; D010669:Phenylthiohydantoin; C540278:enzalutamide; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen; D000069501:Abiraterone Acetate
keywords: Androgen receptor; Biomarkers; Independent; Prostatic neoplasms; Radionuclide imaging